These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 14613420)

  • 21. Patient receipt and understanding of written information provided with isotretinoin and estrogen prescriptions.
    Allen LaPointe NM; Pappas P; Deverka P; Anstrom KJ
    J Gen Intern Med; 2007 Jan; 22(1):98-101. PubMed ID: 17351847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient Access in Restrictive Risk Management Programs: The Case of iPLEDGE.
    Kerr KW; Wosinska ME
    Ther Innov Regul Sci; 2017 Jan; 51(1):16-23. PubMed ID: 30235995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral isotretinoin and topical retinoid use in a series of young patients with ocular melanoma.
    Mishra KK; Scholey JE; Daftari IK; Afshar A; Tsai T; Park S; Quivey JM; Char DH
    Am J Ophthalmol Case Rep; 2020 Sep; 19():100787. PubMed ID: 32760850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Compliance with Pregnancy Prevention Recommendations for Isotretinoin in Estonia in 2012-2016.
    Uusküla A; Pisarev H; Kurvits K; Laius O; Laanpere M; Uusküla M
    Drugs Real World Outcomes; 2018 Jun; 5(2):129-136. PubMed ID: 29790022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Compliance with the pregnancy prevention program among women initiating isotretinoin treatment between 2014 and 2021: A nationwide cohort study on the French Health Data System (SNDS).
    Havet A; Bouvard C; Moskal A; Chanelière M; Massardier J; Lebrun-Vignes B; Jonville-Bera AP; Payet C; Viprey M
    J Eur Acad Dermatol Venereol; 2024 May; ():. PubMed ID: 38764351
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral Antineoplastic Agents: Assessing the Delay in Care.
    Anders B; Shillingburg A; Newton M
    Chemother Res Pract; 2015; 2015():512016. PubMed ID: 26605087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-compliance with pregnancy prevention recommendations for isotretinoin in Korea between 2019-2020.
    Choi EJ; Han JY
    Obstet Gynecol Sci; 2021 Mar; 64(2):201-208. PubMed ID: 33752279
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isotretinoin-induced myositis.
    Hague O; Thanopoulou V; Mangat P; Singh A; Stratton R; Malley T
    Oxf Med Case Reports; 2024 Mar; 2024(3):omae017. PubMed ID: 38532764
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ethical implications of patient information disclosure: Isotretinoin and medication-sharing.
    Babu V; Lipoff JB
    J Am Acad Dermatol; 2024 Jun; ():. PubMed ID: 38866181
    [No Abstract]   [Full Text] [Related]  

  • 30. Granulomatous Periorificial Dermatitis Effectively Managed with Oral Isotretinoin.
    Tambe S; Jerajani H; Pund P
    Indian Dermatol Online J; 2018; 9(1):68-70. PubMed ID: 29441308
    [No Abstract]   [Full Text] [Related]  

  • 31. Fixed-Dose Combination Gel of Adapalene and Benzoyl Peroxide plus Doxycycline 100 mg versus Oral Isotretinoin for the Treatment of Severe Acne: Efficacy and Cost Analysis.
    Penna P; Meckfessel MH; Preston N
    Am Health Drug Benefits; 2014 Jan; 7(1):37-45. PubMed ID: 24991389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study.
    Alhusayen RO; Juurlink DN; Mamdani MM; Morrow RL; Shear NH; Dormuth CR;
    J Invest Dermatol; 2013 Apr; 133(4):907-12. PubMed ID: 23096714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. What is the best approach to reducing birth defects associated with isotretinoin?
    Abroms L; Maibach E; Lyon-Daniel K; Feldman SR
    PLoS Med; 2006 Nov; 3(11):e483. PubMed ID: 17121451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patterns and utilization of isotretinoin for acne from 1984 to 2003: is there need for concern?
    Azoulay L; Oraichi D; Bérard A
    Eur J Clin Pharmacol; 2006 Aug; 62(8):667-74. PubMed ID: 16791584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification and management of oral isotretinoin use inconsistent with product labeling.
    Wert S
    Manag Care Interface; 2003 Mar; 16(3):41-3, 55. PubMed ID: 12715412
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Isotretinoin use and compliance with the Dutch Pregnancy Prevention Programme: a retrospective cohort study in females of reproductive age using pharmacy dispensing data.
    Teichert M; Visser LE; Dufour M; Rodenburg E; Straus SM; De Smet PA; Stricker BH
    Drug Saf; 2010 Apr; 33(4):315-26. PubMed ID: 20297863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in isotretinoin prescribing before and after implementation of the System to Manage Accutane Related Teratogenicity (SMART) risk management program.
    Mendelsohn AB; Governale L; Trontell A; Seligman P
    Pharmacoepidemiol Drug Saf; 2005 Sep; 14(9):615-8. PubMed ID: 15892175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization.
    Cooke CE; Lee HY; Tong YP; Haines ST
    Curr Med Res Opin; 2010 Jan; 26(1):231-8. PubMed ID: 19921965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral isotretinoin: an analysis of its utilization in a managed care organization.
    Chen K; White TJ; Juzba M; Chang E
    J Manag Care Pharm; 2002; 8(4):272-7. PubMed ID: 14613420
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.